Momelotinib long-term safety and survival in myelofibrosis: Integrated analysis of Phase 3 randomized controlled trials

Authors

Srdan Verstovsek, University of Texas MD Anderson Cancer Center
Stephen T Oh, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

7-25-2023

Volume

7

Issue

14

First Page

3582

Last Page

3591

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2022009311

Rights and Permissions

Verstovsek S, Mesa R, Gupta V, Lavie D, Dubruille V, Cambier N, Platzbecker U, Hus M, Xicoy B, Oh ST, Kiladjian JJ, Vannucchi AM, Gerds A, Egyed M, Mayer J, Sacha T, Kawashima J, Morris M, Huang M, Harrison C. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Adv. 2023 Jul 25;7(14):3582-3591. doi: 10.1182/bloodadvances.2022009311. © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Verstovsek, Srdan; Oh, Stephen T; and et al., "Momelotinib long-term safety and survival in myelofibrosis: Integrated analysis of Phase 3 randomized controlled trials." Blood Advances. 7, 14. 3582 - 3591. (2023).
https://digitalcommons.wustl.edu/oa_4/2206

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.